Incyte Corp

INCY:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/15/21 EST
90.56UNCH (UNCH)
Volume
40,170
Close
90.56quote price arrow down-1.48 (-1.61%)
Volume
888,982
52 week range
62.48 - 110.36

...

Loading . . .

KEY STATS

  • Open91.64
  • Day High92.52
  • Day Low89.32
  • Prev Close92.04
  • 52 Week High110.36
  • 52 Week High Date07/07/20
  • 52 Week Low62.48
  • 52 Week Low Date03/23/20
  • Market Cap19,805.47M
  • Shares Out218.70M
  • 10 Day Average Volume1.20M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • 1 Year % Change12.33

RATIOS/PROFITABILITY

  • EPS (TTM)-1.57
  • P/E (TTM)-57.70
  • Fwd P/E (NTM)28.69
  • EBITDA (MRQ)-227.63M
  • ROE (MRQ)-13.90%
  • Revenue (MRQ)2,456.58M
  • Gross Margin (MRQ)95.70%
  • Net Margin (MRQ)-13.62%
  • Debt To Equity (MRQ)1.95%

EVENTS

  • Earnings Date02/11/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest INCY News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia...
Herve Hoppenot
Chairman
Christiana Stamoulis
Chief Financial Officer
Maria Pasquale
Executive Vice President
Paula Swain
Executive Vice President
Steven Stein M.D.
Executive Vice President
Address
1801 Augustine Cut off
Wilmington, DE
19803-4404
United States